Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 16;13:116. doi: 10.1186/s13073-021-00926-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — KRAS mutation fraction dynamics under treatment in CET SR BoC71 tumors. a KRAS-G12V specific BEAMing assay in BoC71 PDX models. Fluorescence dot plots are shown with wildtype population plotted on the Y-axis and mutant population on the x-axis. Only one sample (BoC71 F4 C3) showed a high percentage of G12V mutation, resulting in 22.27% mutant fraction. All other samples are negative for KRAS G12V, showing values below our detection limit of 0.02% mutant fraction. Sample BoC71 F4 C4 shows a strong shift of the majority of the wildtype population to the right uncharacteristic for the G12V mutation. This shift stems from the G12C KRAS mutation which this single KRAS analyte analysis cannot detect. F, PDX generation starting with F0; K, untreated control tumor; 5dC, 5 days CET treated; C, CET secondary resistant. b Growth curves of KRAS mutated SR tumor BoC71 C3 untreated (U), treated either only for the indicated time frame (shaded gray area) and taken out for analysis at the end of treatment or taken out following a treatment pause and doubling of the tumor volume (CI). c Fractional abundance of KRAS mutation determined by digital droplet PCR for corresponding experimental set-ups. Data are shown as mean values ± SEM (error bars)